1-17 of 17
Yiling Lu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation

Tapsi Kumar, Evie Hobbs, Fei Yang, Jeffrey T. Chang, Alejandro Contreras, Edwin Roger Parra Cuentas, Haven Garber, Sanghoon Lee, Yiling Lu, Marion E. Scoggins, Beatriz E. Adrada, Gary J. Whitman, Banu K. Arun, Elizabeth A. Mittendorf, Jennifer K. Litton
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3669–3676.
https://doi.org/10.1158/1078-0432.CCR-21-1278
Published: 01 September 2022
View article titled, Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary <em>BRCA</em> Mutation
Open the PDF for Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary <em>BRCA</em> Mutation in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas

Shiyou Wei, Delong Yin, Shengnan Yu, Xiang Lin, Milan R. Savani, Kuang Du, Yin Ku, Di Wu, Shasha Li, Hao Liu, Meng Tian, Yaohui Chen, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Stephen T. Keir, Eric T. Sugarman, Rebecca A. Deek, Marilyne Labrie, Mustafa Khasraw, Yiling Lu, Gordon B. Mills, Meenhard Herlyn, Kongming Wu, Lunxu Liu, Zhi Wei, Keith T. Flaherty, Kalil Abdullah, Gao Zhang, David M. Ashley
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2180–2195.
https://doi.org/10.1158/1078-0432.CCR-21-0833
Published: 13 May 2022
View article titled, Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Open the PDF for Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas in another window
Includes: Supplementary data
Journal Articles

A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

Shengnan Yu, Shiyou Wei, Milan Savani, Xiang Lin, Kuang Du, Ilgen Mender, Silvia Siteni, Themistoklis Vasilopoulos, Zachary J. Reitman, Yin Ku, Di Wu, Hao Liu, Meng Tian, Yaohui Chen, Marilyne Labrie, Casey M. Charbonneau, Eric Sugarman, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Wen Jiang, Roger E. McLendon, Edward Pan, Mustafa Khasraw, Kyle M. Walsh, Yiling Lu, Meenhard Herlyn, Gordon Mills, Utz Herbig, Zhi Wei, Stephen T. Keir, Keith Flaherty, Lunxu Liu, Kongming Wu, Jerry W. Shay, Kalil Abdullah, Gao Zhang, David M. Ashley
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6800–6814.
https://doi.org/10.1158/1078-0432.CCR-21-0374
Published: 15 December 2021
View article titled, A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas
Open the PDF for A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas in another window
Includes: Supplementary data
Journal Articles

Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

Charles Marusak, Varsha Thakur, Yuan Li, Juliano T. Freitas, Patrick M. Zmina, Vijay S. Thakur, Mayland Chang, Ming Gao, Jiufeng Tan, Min Xiao, Yiling Lu, Gordon B. Mills, Keith Flaherty, Dennie T. Frederick, Benchun Miao, Ryan J. Sullivan, Tabea Moll, Genevieve M. Boland, Meenhard Herlyn, Gao Zhang, Barbara Bedogni
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 6039–6050.
https://doi.org/10.1158/1078-0432.CCR-19-2773
Published: 13 November 2020
View article titled, Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Open the PDF for Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract NT-098: WINDOW OF OPPORTUNITY TRIAL: ASSESSING THE ADAPTIVE RESPONSE OF HGSOC TO PARPI FOR INFORMED COMBINATION THERAPIES

Marilyne Labrie, Tae-Beom Kim, Zhenlin Ju, Sanghoon Lee, Yiling Lu, Ken Chen, Gordon B. Mills, Shannon N. Westin
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): NT-098.
https://doi.org/10.1158/1557-3265.OVCASYMP18-NT-098
Published: 15 November 2019
View article titled, Abstract NT-098: WINDOW OF OPPORTUNITY TRIAL: ASSESSING THE ADAPTIVE RESPONSE OF HGSOC TO PARPI FOR INFORMED COMBINATION THERAPIES
Journal Articles

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma

Gao Zhang, Lawrence W. Wu, Ilgen Mender, Michal Barzily-Rokni, Marc R. Hammond, Omotayo Ope, Chaoran Cheng, Themistoklis Vasilopoulos, Sergio Randell, Norah Sadek, Aurelie Beroard, Min Xiao, Tian Tian, Jiufeng Tan, Umar Saeed, Eric Sugarman, Clemens Krepler, Patricia Brafford, Katrin Sproesser, Sengottuvelan Murugan, Rajasekharan Somasundaram, Bradley Garman, Bradley Wubbenhorst, Jonathan Woo, Xiangfan Yin, Qin Liu, Dennie T. Frederick, Benchun Miao, Wei Xu, Giorgos C. Karakousis, Xiaowei Xu, Lynn M. Schuchter, Tara C. Mitchell, Lawrence N. Kwong, Ravi K. Amaravadi, Yiling Lu, Genevieve M. Boland, Zhi Wei, Katherine Nathanson, Utz Herbig, Gordon B. Mills, Keith T. Flaherty, Meenhard Herlyn, Jerry W. Shay
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4771–4784.
https://doi.org/10.1158/1078-0432.CCR-17-2773
Published: 01 October 2018
View article titled, Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Open the PDF for Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma in another window
Includes: Multimedia, Supplementary data
Journal Articles

Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Clemens Krepler, Min Xiao, Katrin Sproesser, Patricia A. Brafford, Batool Shannan, Marilda Beqiri, Qin Liu, Wei Xu, Bradley Garman, Katherine L. Nathanson, Xiaowei Xu, Giorgos C. Karakousis, Gordon B. Mills, Yiling Lu, Tamer A. Ahmed, Poulikos I. Poulikakos, Giordano Caponigro, Markus Boehm, Malte Peters, Lynn M. Schuchter, Ashani T. Weeraratna, Meenhard Herlyn
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1592–1602.
https://doi.org/10.1158/1078-0432.CCR-15-1762
Published: 31 March 2016
View article titled, Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Open the PDF for Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies in another window
Includes: Supplementary data
Journal Articles

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer

Karina E. Hew, Philip C. Miller, Dorraya El-Ashry, Jun Sun, Alexandra H. Besser, Tan A. Ince, Mengnan Gu, Zhi Wei, Gao Zhang, Patricia Brafford, Wei Gao, Yiling Lu, Gordon B. Mills, Joyce M. Slingerland, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 935–947.
https://doi.org/10.1158/1078-0432.CCR-15-0534
Published: 14 February 2016
View article titled, MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer
Open the PDF for MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer

Ji-Yeon Yang, Henrica M.J. Werner, Jie Li, Shannon N. Westin, Yiling Lu, Mari K. Halle, Jone Trovik, Helga B. Salvesen, Gordon B. Mills, Han Liang
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 513–523.
https://doi.org/10.1158/1078-0432.CCR-15-0104
Published: 14 January 2016
View article titled, Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer
Open the PDF for Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

The development of an efficient procedure for protein extraction from formalin fixed and paraffin embedded tissues and analysis of its application to reverse phase protein arrays

Huifang Guo, Wenbin Liu, Zhenlin Zhu, Eric Jonasch, Gordon B. Mills, Bryan Hennessy, Yiling Lu, Dimitra Tsavachidou
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): A12.
https://doi.org/10.1158/DIAG-10-A12
Published: 15 August 2014
View article titled, The development of an efficient procedure for protein extraction from formalin fixed and paraffin embedded tissues and analysis of its application to reverse phase protein arrays
Journal Articles

Phosphoproteomics and mass-action modeling to predict optimal drug combination in signaling networks

Fabiana C. Morales, Sergio Iadevaia, Yiling Lu, Prahlad Ram, Gordon B. Mills, UT M.D.
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): B32.
https://doi.org/10.1158/DIAG-10-B32
Published: 15 August 2014
View article titled, Phosphoproteomics and mass-action modeling to predict optimal drug combination in signaling networks
Journal Articles

Abstract B74: Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors

Intidhar Labidi-Galy, Adam Clauss, Vivian Ng, Sekhar Duraisamy, Kevin M. Elias, Erhan Bilal, Rachel A. Davidowitz, Yiling Lu, Gayane Badalian-Very, Hui-Ying Piao, Un-Beom Kang, Scott Ficarro, Shridar Ganesan, Gordon B. Mills, Jarrod Marto, Ronny Drapkin
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): B74.
https://doi.org/10.1158/1078-0432.OVCA13-B74
Published: 13 May 2014
View article titled, Abstract B74: Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors
Journal Articles

Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer

Andrew Sewell, Brandee Brown, Asel Biktasova, Gordon B. Mills, Yiling Lu, Darren R. Tyson, Natalia Issaeva, Wendell G. Yarbrough
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (9): 2300–2311.
https://doi.org/10.1158/1078-0432.CCR-13-2585
Published: 30 April 2014
View article titled, Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer
Open the PDF for Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo

Fiona Simpkins, Pedro Hevia-Paez, Jun Sun, Wendy Ullmer, Candace A. Gilbert, Thiago da Silva, Ali Pedram, Ellis R. Levin, Isildinha M. Reis, Brian Rabinovich, Diana Azzam, Xiang-Xi Xu, Tan A. Ince, Ji-Yeon Yang, Roel G.W. Verhaak, Yiling Lu, Gordon B. Mills, Joyce M. Slingerland
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 5911–5923.
https://doi.org/10.1158/1078-0432.CCR-12-1257
Published: 06 November 2012
View article titled, Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy

Mark S. Carey, Roshan Agarwal, Blake Gilks, Kenneth Swenerton, Steve Kalloger, Jennifer Santos, Zhenlin Ju, Yiling Lu, Fan Zhang, Kevin R. Coombes, Dianne Miller, David Huntsman, Gordon B. Mills, Bryan T. Hennessy
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (10): 2852–2860.
https://doi.org/10.1158/1078-0432.CCR-09-2502
Published: 13 May 2010
View article titled, Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy
Open the PDF for Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Pharmacodynamic Markers of Perifosine Efficacy

Bryan T. Hennessy, Yiling Lu, Enrique Poradosu, Qianghua Yu, Shuangxing Yu, Hassan Hall, Mark S. Carey, Murali Ravoori, Ana Maria Gonzalez-Angulo, Robert Birch, I. Craig Henderson, Vikas Kundra, Gordon B. Mills
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (24): 7421–7431.
https://doi.org/10.1158/1078-0432.CCR-07-0760
Published: 19 December 2007
View article titled, Pharmacodynamic Markers of Perifosine Efficacy
Open the PDF for Pharmacodynamic Markers of Perifosine Efficacy in another window
Includes: Supplementary data
Journal Articles

Overexpression of Edg-2/vzg-1 Induces Apoptosis and Anoikisin Ovarian Cancer Cells in a Lysophosphatidic Acid-independent Manner

Tatsuro Furui, Ruth LaPushin, Muling Mao, Humera Khan, Steve R. Watt, Mary-Ann V. Watt, Yiling Lu, Xianjun Fang, Shinichi Tsutsui, Zahid H. Siddik, Robert C. Bast, Jr., Gordon B. Mills
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (12): 4308–4318.
Published: 01 December 1999
View article titled, Overexpression of Edg-2/vzg-1 Induces Apoptosis and Anoikisin Ovarian Cancer Cells in a Lysophosphatidic Acid-independent Manner
Open the PDF for Overexpression of Edg-2/vzg-1 Induces Apoptosis and Anoikisin Ovarian Cancer Cells in a Lysophosphatidic Acid-independent Manner in another window